title: Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
abstract: Successful phenotype-genotype correlation is critically dependent on precise definition and reporting of end points in clinical trials. An uniform nomenclature for "deep phenotyping" of metastatic sites in patients with castration-resistant prostate cancer should be mandated in future clinical drug development.
authors.affiliation: Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Che-Kai
authors.initials: CK
authors.lastname: Tsao
authors.affiliation: Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
authors.affiliation: Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: William.oh@mssm.edu.
authors.forename: William K
authors.initials: WK
authors.lastname: Oh
mesh_terms: D002986:Clinical Trials as Topic / Q000592:standards*; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D010641:Phenotype; D064129:Prostatic Neoplasms, Castration-Resistant / Q000473:pathology*; D009626:Terminology as Topic